BioNTech

Phase A — Understand the business

Lens 1 · Company Overview

BioNTech is a Mainz, Germany-based immunotherapy company — the mRNA pioneer that, with Pfizer, made Comirnaty, the world's leading COVID-19 vaccine. That partnership minted one of the great cash windfalls in biotech history and left the company with a roughly €17.2bn cash-and-investments war chest at end-2025. The strategic story today is the deliberate redeployment of that pandemic fortune into oncology — BioNTech is trying to convert a one-product vaccine company into a multi-asset cancer-immunotherapy "powerhouse."

The business has two engines moving in opposite directions:

1. The COVID annuity (declining). BioNTech books its share of Comirnaty economics; Pfizer commercializes ex-Germany and provides the profit-share figures. In FY2025, COVID-19 vaccine revenue was €1,995.3m, 70% of total. The franchise still held >50% global market share in the fall 2025 season across 69 markets — but management explicitly guides this lower in 2026 in both the US and Europe.
2. The oncology pipeline (the actual thesis). 16 clinical oncology programs, >25 Phase 2/3 trials, anchored by pumitamig (BNT327), a PD-L1×VEGF-A bispecific now co-developed with Bristol Myers Squibb.

Contract structure / key payment terms. Two relationships dominate revenue:

• Pfizer — the Comirnaty collaboration, a gross-profit-share arrangement. Pfizer = €1,602.0m, 56% of FY2025 revenue. Revenue is partly booked on preliminary estimates Pfizer provides, which "are likely to change" — a recurring, disclosed estimation risk.
• BMS — the June 2025 pumitamig deal. BioNTech received a $1.5bn upfront in FY2025, is owed $2.0bn in non-contingent anniversary payments through 2028, and up to $7.6bn in development/regulatory/commercial milestones — up to ~$11.1bn total. BMS already contributed €613.0m (21%) of FY2025 revenue as out-licensing income.
• A third, lumpy customer: the German Federal Ministry of Health, €627.5m (22%) in FY2025 — largely legacy COVID supply.

Main competitors: in COVID, Moderna and (to a lesser degree) Novavax/protein vaccines; in the oncology lead program, Summit Therapeutics/Akeso (ivonescimab) and Pfizer (PF-08634404) — the other PD-(L)1×VEGF bispecifics — and ultimately Merck's Keytruda franchise that this class aims to displace.

Lens 2 · Supply Chain

BioNTech is largely a develop-and-partner company; it does not run a classic physical supply chain so much as a network of co-development partners and CDMO-style manufacturing relationships.

Upstream → BioNTech → end patient, named stakeholders:

• mRNA / drug-substance inputs & manufacturing: BioNTech operates its own manufacturing footprint (Mainz, Marburg, plus the InstaDeep AI layer for design), and is consolidating/adjusting that footprint through 2027 as COVID volumes fall — explicitly flagged as a multi-year capacity reduction. This is a cost-out story, not a growth-capex story.
• COVID commercialization partner: Pfizer — manufactures, distributes and sells Comirnaty across most of the world and provides the profit-share data. This is the single largest external dependency on the revenue side.
• Oncology co-development partners (the new "supply chain" of assets): Bristol Myers Squibb (pumitamig, global co-dev/co-commercial); Roche/Genentech (autogene cevumeran / BNT122, iNeST); DualityBio (the ADC engine — BNT323/trastuzumab pamirtecan, BNT324, BNT325); Regeneron (BNT111, BNT116 melanoma/NSCLC combos); Genmab (BNT314/GEN1059); OncoC4, MediLink, Fosun Pharma (regional/asset-specific); plus the Biotheus acquisition (Feb 2025) that bought back full global pumitamig rights, and CureVac (Dec 2025) folding in a German mRNA rival.
• Funders of infectious-disease programs: the Gates Foundation and CEPI part-fund global-health programs.

Chokepoint / single-source observations. The genuine concentration is commercial, not industrial: 56% of revenue routes through one partner (Pfizer) on a franchise in structural decline, and the entire growth case rests on a small handful of partnered assets — above all one molecule (pumitamig) where BMS co-controls. There is no semiconductor-style physical bottleneck; the bottleneck is clinical-readout risk and partner dependency.

Lens 3 · Competitive Advantages (moats)

What's genuinely durable:

• The balance sheet is the moat. €17.2bn cash/investments against a €23bn market cap and trivial debt (€267m) means BioNTech can fund an enormous Phase 3 program (8 global pumitamig registrational trials by end-2026) out of pocket, plus buy assets (Biotheus, CureVac) and run a $1bn buyback, while peers must raise dilutive equity. In a sector where the binding constraint is usually cash-to-next-catalyst, BioNTech has effectively removed that constraint for years.
• mRNA platform + InstaDeep AI + manufacturing. A real, validated, at-scale mRNA platform (Comirnaty is the proof) plus owned manufacturing and an AI/ML drug-design layer. The individualized-neoantigen (iNeST) capability is genuinely differentiated technology.
• IP estate in mRNA/LNP — though this cuts both ways (see Lens 10: BioNTech is a defendant in the Moderna patent wars).

Where the moat is thin / contested:

• The lead oncology asset is a fast-follower, not a first-mover. Pumitamig is a "fast follower to Akeso and Summit's ivonescimab" and analysts repeatedly note it "looks similar to ivonescimab again". Bargaining power over the standard of care it must displace (Keytruda) is unproven; being second in a class is a weaker position than the cash pile implies.
• Bargaining power over customers in COVID is eroding as demand normalizes and contracts roll off; management is now "defending" share, not setting price.

Net: the financial moat is A-grade; the product moat in the growth franchise is, as of June 2026, still hypothetical and contested.

Lens 4 · Segments

BioNTech reports as a single operating segment but discloses revenue by type and by customer (Note 6). All figures €m, IFRS:

By revenue type:

By customer:

Trend & cause. Total revenue is deceptively roughly flat YoY (€2,751m → €2,870m, +4%), but the mix shift is the whole story: COVID revenue fell €437m (−18%) and was masked by a one-time €613m of BMS out-licensing income booked on the pumitamig deal. Strip the deal and the underlying franchise is shrinking double-digits. Geographic detail is not separately disaggregated in Note 6 beyond the customer cut (Pfizer ex-Germany commercializes globally; the German Ministry is the domestic channel). The FY2026 guide (€2.0–2.3bn) confirms management expects total revenue to fall as COVID declines and the BMS upfront doesn't recur at the same magnitude.

---

Phase B — Measure performance (operating + clinical overlay)

Lens 5 · Earnings Result (latest print)

Consolidated Statement of Profit or Loss (€m, IFRS):

Read: FY2025 was a €1,136m net loss, the second consecutive loss year and a widening one (loss-per-share €4.70 vs €2.77). The driver is structural: R&D held at ~€2.1bn while gross profit collapsed with COVID volume, and "other operating expense" ballooned to €1,088m (up from €811m) — this captures inventory write-downs / redundant COVID manufacturing capacity and acquisition/restructuring costs, exactly the costs flagged in the forward-looking risk language. Finance income (€424m) — interest on the cash pile — is now a material earnings cushion and the reason the pre-tax loss (€1,051m) is smaller than the operating loss.

Balance sheet (end-2025, €m): Cash & equivalents 7,675.4; current other financial assets (securities) 7,201.8; non-current other financial assets 2,554.2 → the ~€17.2bn liquidity aggregate management cites. Total assets 21,988.6; total equity 19,224.2; total liabilities only 2,764.4 (lease/borrowings ~€267m). Inventories fell to €110.7m from €283.3m and receivables to €924.2m from €1,463.9m — consistent with a shrinking COVID franchise, not a red flag.

Latest quarterly print — Q1 2026 (reported 2026-05-05): Revenue €118.1m (vs €182.8m PY), net loss €531.9m (adj. €494.6m), diluted EPS €(2.10). Cash/investments €16.8bn. FY2026 guidance reaffirmed: revenue €2.0–2.3bn; adj. R&D €2.2–2.5bn; adj. SG&A €700–800m. Announced a $1.0bn buyback over 12 months. Q1 is seasonally tiny for a COVID-weighted top line (revenue lands in H2 vaccination season), so the €118m is not the run-rate — but it confirms the structural-loss trajectory and a heavy 2026 spend year.

Unusual vs own history: the swing from €930m net profit (2023) to €1.1bn net loss (2025) on roughly flat headline revenue is the signature of a company that chose to spend its windfall — R&D + M&A + write-downs — rather than harvest it. That's a strategic choice, legible in the numbers, not an accounting surprise.

Lens 5b · Pipeline by phase (clinical overlay — this is the company)

Source: 20-F Item 4 business section, updated with 2026 readouts.

LEAD — Pumitamig (BNT327/BMS986545), PD-L1×VEGF-A bispecific. Partner: BMS (50/50 global). The whole equity thesis. ~16-program web of trials; 8 global registrational trials planned ongoing by end-2026. Highlights:

Plus a deep bench of pumitamig + proprietary-ADC combinations (BNT323/324/325/326, BNT314, BNT3212/3213). The catalyst that matters most: the first global Phase 3 readouts (SCLC, TNBC, NSCLC Ph2 portion) land 2026.

iNeST — Autogene cevumeran (BNT122). Partner: Roche/Genentech. MIXED-TO-NEGATIVE so far:

• IMCODE001 (1L advanced melanoma): MISSED primary PFS endpoint (topline Mar 2025); only a numerical OS trend.
• BNT122-01 (adjuvant CRC, ctDNA+): interim analysis crossed the futility boundary; DSMB recommended termination but the trial continued per protocol; final readout pushed from 2026 to 2027. This is the program with the most upside-if-it-works (the famous pancreatic/CRC neoantigen story) and it is now slower and de-risked downward.
• IMcode004 (adjuvant urothelial): discontinued.

FixVac (off-the-shelf mRNA): BNT111 (melanoma — met primary ORR, but no further advanced-melanoma development planned); BNT113 (HPV16+ HNSCC — FDA Fast Track Dec 2025, Ph3 interim expected 2026); BNT116 (NSCLC, Phase 1/2).

ADCs (DualityBio): Trastuzumab pamirtecan (BNT323/DB-1303), HER2 — Fast Track + Breakthrough Therapy; BLA planned 2026 in 2L endometrial cancer (closest asset to an approval). BNT324/DB-1311 (B7H3; Fast Track in mCRPC; Phase 3 planned 2026).

Pipeline verdict: broad, real, and overwhelmingly front-loaded onto pumitamig. The mRNA-cancer-vaccine dream (iNeST) — the reason many bought the stock — has stumbled (melanoma miss, CRC futility-boundary, slip to 2027). The near-term value now rides on a bispecific antibody that is second in its class.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts in the research layer; from public call coverage:

• Tone shift over the last several quarters: from "COVID cash machine / optionality" to "oncology execution under a clock." Management language is now dominated by registrational-trial counts, catalyst timing, and operational efficiency / footprint consolidation — the vocabulary of a company managing a decline while funding a pivot.
• What they keep saying: "global immunotherapy powerhouse," "pumitamig," "multiple registrational trials," "disciplined capital allocation," €17bn balance-sheet strength.
• What they stopped saying: bullish COVID-demand framing; the iNeST/individualized-vaccine narrative has been quietly de-emphasized after the melanoma miss and CRC slip.
• New, jarring note (Mar 2026): the founder-departure announcement (Lens 9) injected a governance/continuity theme the prior calls never had.

Lens 7 · Comps + Catalyst calendar (clinical overlay)

Peer multiples table. Provenance-critical — multiples are `` or n/a. BioNTech is structurally hard to comp on P/E (it's loss-making) and on EV/Sales (its EV is tiny because ~€17bn cash nets against a ~€23bn cap). The honest read is enterprise value of roughly $9bn for the entire oncology pipeline + a declining COVID annuity.

I will not fabricate Summit/BMS/Merck multiples — n/a.

Catalyst calendar (what de-risks or kills the thesis, and when):

Lens 8 · Stock-Price Catalysts (what actually moves the tape)

Pattern over the last ~5 years:

• 2020–2021: the COVID supercycle — the stock 10x'd on Comirnaty authorization, supply deals and profit upgrades. The market reacted almost entirely to vaccine revenue and order flow.
• 2022–2024: the de-rate — as COVID demand normalized and guidance fell, the stock gave back most of the gains. Earnings/guidance cuts were the movers.
• 2025: re-rating on oncology + the BMS deal — the June 2025 ~$11bn BMS pumitamig partnership was the single biggest positive catalyst, validating the asset with big-pharma cash.
• March 10, 2026: the founder-departure crash — shares fell ~20–22% intraday on news that Sahin and Türeci would leave to start a new mRNA company. The biggest single down-move in years, and it was governance, not data.

What the market actually reacts to for BNTX: (1) COVID revenue/guidance (legacy, fading), (2) pumitamig data and deal validation (now the swing factor), and (3) key-person/governance risk — uniquely acute here because the founders are also the science and ~33% of the votes.

---

Phase C — Judge people & books

Lens 9 · Management

• Prof. Ugur Sahin, M.D. (CEO/co-founder) and Prof. Özlem Türeci, M.D. (CMO/co-founder) — the married scientific founders, serial biotech builders (Ganymed 2001 → sold to Astellas; BioNTech 2008). Track record: world-class — they delivered the first authorized COVID-19 vaccine at unprecedented speed and built the mRNA platform. Quantified: turned a private German biotech into a company that generated >€10bn of cumulative pandemic profit and a €17bn balance sheet.
• Skin in the game (extreme): Sahin beneficially owns 16.4% (via Medine GmbH + direct). The Strüngmann family via ATHOS KG / AT Impf GmbH owns 40.3% and has "de facto control" of the AGM. Board+management as a group = 17.1%. This is a founder/family-controlled company — minority public holders are along for the ride.
• Capital-allocation history: aggressive redeployment of the windfall — funded a huge internal Phase 3 build, bought Biotheus (Feb 2025, to regain global pumitamig rights; ~€280m net consideration after settling the pre-existing license) and CureVac (Dec 2025, ~$1.25bn all-stock, ending a patent feud), partnered pumitamig with BMS for up to $11bn, and launched a $1bn buyback (May 2026). ROE/ROIC are negative on their current watch (they are spending, not earning) — defensible as investment, but the value-creation verdict is entirely deferred to pipeline outcomes.
• THE red flag — key-person exit (Mar 10, 2026): both founders announced they will leave by end-2026 to start a new, independent next-generation mRNA company, to which BioNTech will contribute mRNA rights/tech for a minority stake. The Supervisory Board has opened an executive search. This is a profound governance event: the architects of the science and a third of the voting power are walking out just as the oncology bet enters its make-or-break readouts — and they're starting a competing mRNA venture with the company's own technology. The market's −20% reaction was rational.
• Archetype: founder-scientists, not professional operators — which is exactly why their departure is so destabilizing for this specific company at this specific moment.

Lens 10 · Forensic Red Flags

Ground: FY2025 20-F.

• Revenue recognition / estimation risk (disclosed, real): a chunk of COVID revenue is booked on Pfizer's preliminary profit-share estimates that "are likely to change," and BMS milestone/collaboration revenue involves judgment on performance obligations. Not fraud — but reported revenue carries genuine estimation uncertainty management itself flags.
• "Other operating expense" €1,088m — the line to watch. Up €277m YoY; this absorbs COVID inventory write-downs, redundant-capacity charges and M&A/restructuring. It's where a vaccine company in decline parks the pain. Legitimate, but it makes the operating loss noisier and worth tracking quarter to quarter.
• Intangibles / goodwill from the deal spree: Other intangibles jumped to €1,606m from €790m (Biotheus/CureVac IP, in-process R&D). Goodwill €367.9m, all allocated to the "immunotherapies" CGU. In-process R&D for unapproved assets isn't amortized and is impairment-tested — a pumitamig or iNeST failure could trigger a write-down. Watch this as the pipeline reads out.
• SBC: total share-based payment expense €106.3m (2025) — modest relative to scale; not flattering non-GAAP in an egregious way.
• PFIC status: BioNTech "was a PFIC for 2025" — a direct consequence of the enormous cash/securities pile (passive assets). A real adverse US-tax consideration for US ADS holders, not an accounting irregularity, but it belongs in any diligence.
• Cash flow vs earnings: the loss is cash-backed-down (write-downs are non-cash; €424m finance income is real interest). No sign of receivables/inventory outrunning revenue — both fell. The balance sheet is pristine.

Regulatory findings (required sub-section). Read regulatory/regulatory-findings.md:

• SEC Litigation Releases: none naming BioNTech (EDGAR EFTS LR search, 2021–2026).
• AAERs: none (EDGAR EFTS AAER search, 2021–2026).
• Non-SEC / litigation (material, `` + 20-F Item 3): the dominant legal exposure is the Moderna mRNA/LNP patent war. The Düsseldorf Regional Court ruled Comirnaty infringes a Moderna patent (EP'949) and ordered BioNTech/Pfizer to account for profits and pay damages; the UK High Court (2024) likewise found EP'949 infringed (while invalidating EP'565); offsetting, the US PTAB (Mar 2025) ruled two Moderna patents unpatentable. BioNTech is also pursuing nullity/opposition actions against CureVac IP (now mooted by the acquisition) and Moderna patents across Europe. Net: a material, unquantified contingent royalty/damages liability on the COVID franchise, jurisdiction-by-jurisdiction and unresolved — a genuine overhang, though Pfizer typically shares COVID-litigation costs.
• Separately, the inherited CureVac/EU Commission APA audit (Deloitte findings on the terminated CVnCoV advance-purchase agreement) is a smaller, inherited contingency BioNTech now owns.
• Summary: No SEC enforcement or accounting-fraud findings (verified via SEC EDGAR EFTS LR + AAER and 20-F as of 2026-06-18). The real legal risk is patent infringement on Comirnaty (Moderna), not accounting.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection + runway-to-catalyst (clinical overlay)

BioNTech is loss-making with revenue in structural decline and value concentrated in unapproved assets, so a precise three-year EPS line is low-information — the right frame is runway-to-catalyst + scenario EPS, all `` off the disclosed base.

Base inputs (labeled): FY2026 revenue €2.0–2.3bn (guided), adj. R&D €2.2–2.5bn (guided), adj. SG&A €0.7–0.8bn (guided), cash €16.8bn Q1'26; ~251.3m shares out.

• Runway (the metric that actually matters): with ~€16.8bn liquidity, an annual operating cash burn plausibly €1.5–2.5bn, BioNTech has roughly 6–10+ years of runway even before further BMS milestones — i.e., runway dwarfs every near-term catalyst. It will never be a financing-risk story; it is purely a does-the-science-work story. This is the single most important conclusion of the projection.
• FY2026 base EPS: continued net loss of roughly €(2.50)–€(3.50)/share. Consensus shows a loss-per-share around $(2.29)–$(2.30) for 2026.
• FY2027–2028: path is binary on pumitamig. Bear: COVID keeps fading, pumitamig disappoints vs ivonescimab, losses persist €(2)–€(3)/share, impairments bite. Base: pumitamig delivers credible Phase 3 wins in 1–2 indications, first ADC/HNSCC approvals arrive, COVID stabilizes — losses narrow toward breakeven by ~2028 as BMS milestones + early oncology sales build. Bull: pumitamig becomes a multi-indication standard-of-care challenger to Keytruda and oncology revenue inflects — multi-€-billion franchise, return to sustained profit, EPS swinging positive. The spread between these is enormous and not resolvable from today's data.

Forecast log: per --watchlist unattended rules, no forecast.ts create run. The binary worth tracking when promoted: "Pumitamig meets primary endpoint in its first global Phase 3 (SCLC or TNBC), reading out by 2026-12-31."

Lens 12 · Bull vs Bear

Bull case. You are buying a $9bn-enterprise-value call option on the best-funded oncology pipeline in biotech. The €17bn cash pile means zero financing risk for ~a decade; the BMS partnership put big-pharma validation and up to $11bn behind the lead asset; pumitamig is in a class (PD-(L)1×VEGF) that has already shown it can beat Keytruda (ivonescimab's HARMONi-2), so the mechanism is de-risked even if BioNTech is second; eight registrational trials read out across 2026–2027 across huge indications (lung, breast, GI); the ADC bench and a near-term endometrial BLA add shots on goal; and you're paid to wait via a $1bn buyback. Downside is cushioned by cash that's ~70% of the market cap. Contrarian bull line: the market is pricing BNTX like a melting COVID stock, when the cash-adjusted price is a cheap option on a validated oncology mechanism.

Bear case (permanent-impairment risks). (1) Pumitamig is second-best and could stay there — if ivonescimab (and Pfizer's entrant) win the registrational races and the label/commercial war, BioNTech's lead asset becomes a me-too in a price-competed class, and the entire growth thesis evaporates. (2) The mRNA-cancer-vaccine dream is already cracking — iNeST missed in melanoma and hit a futility boundary in CRC (slipped to 2027); if the platform's flagship differentiated idea doesn't work, much of the "powerhouse" narrative is hollow. (3) The founders are leaving to compete — losing the scientific architects and 33% of the votes, mid-pivot, to a rival mRNA startup seeded with BioNTech's own tech, is a structural governance impairment with no clean fix. Pre-mortem (18 months out, thesis broken): ivonescimab's US data lands first and looks better; pumitamig's first global Phase 3 reads out ambiguous; the new CEO is a caretaker; iNeST CRC final analysis underwhelms in 2027; the stock is a €17bn cash shell the market values at less than cash because it's burning €2bn/yr with no clear winner — a classic "great balance sheet, no franchise" value trap. Multiples: not "too high" on cash-adjusted EV, but the equity premium over net cash ($6–9bn) is pure pipeline hope that the data has not yet earned.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case: The bull rests on three things and I can attack all three. (a) "Cheap option on cash." The €17bn is real, but it's a depreciating option — they're burning ~€2bn/yr and just spent on Biotheus, CureVac and a buyback; cash that funds losses and me-too trials isn't a margin of safety, it's a slow leak with a logo. (b) "Validated mechanism." Validated for ivonescimab, not pumitamig — and "looks similar to ivonescimab again" is faint praise when ivonescimab is ahead with pivotal US data reading out first. In oncology, second-to-market in a crowded PD-(L)1×VEGF field (BNTX/BMS, Summit/Akeso, Pfizer, plus Merck's sac-TMT combos) means pricing pressure and share loss the moment more than one drug works. (c) "Powerhouse pipeline." The differentiated part — individualized mRNA cancer vaccines (iNeST) — has already disappointed (melanoma PFS miss, CRC futility boundary, 2027 slip). Strip iNeST and BioNTech is a cash-rich licensor of a fast-follower antibody and some partnered ADCs — a fine biotech, not a €23bn one. Most dangerous competitor bulls underestimate: Summit/Akeso — they own the class-defining asset and the first-mover data. Worst capital-allocation/governance facts: founder-controlled with 40% family de-facto control and the founders now exiting to a competing venture with company IP — minority holders have neither control nor continuity. What must hold for today's price: that pumitamig wins multiple Phase 3s and commercializes against entrenched/cheaper rivals, that COVID stabilizes rather than collapses, and that a post-founder management team executes a multi-year oncology launch. If growth disappoints 20–30% (pumitamig stumbles): the equity compresses toward net cash — call it the high-$50s–$60s ADS (≈ cash value), i.e., meaningful downside from ~$89. Single permanent-impairment scenario: pumitamig fails its first global Phase 3s while ivonescimab succeeds — plausible (these are fast-follower trials against a leader), and it would gut the thesis.

Lens 14 · Management Questions (ordered by information value)

1. With the founders departing by end-2026, what is the specific succession plan for the CEO and CMO, and how do you retain the scientific leadership and R&D talent through the pumitamig readouts?
2. How does the new founder-led mRNA company's access to BioNTech technology not create a competitor, and what exactly did BioNTech get (and give up) in that arrangement?
3. On what basis do you believe pumitamig can win share against ivonescimab, given it is later to market and the data so far "looks similar"? What is the differentiation thesis?
4. What is the go/no-go decision framework and timing for the autogene cevumeran adjuvant-CRC program after the futility-boundary crossing and the slip to 2027?
5. How should investors think about the division of pumitamig economics with BMS — booked revenue, cost-share, and milestone cadence — across 2026–2028?
6. What is your expected steady-state COVID-19 vaccine revenue floor, and at what point does it stop declining?
7. How much of the ~€1.1bn "other operating expense" is non-recurring COVID write-down vs. structural, and what is the trajectory as footprint consolidation completes in 2027?
8. What is the realistic peak-sales envelope you underwrite internally for pumitamig across its registrational indications?
9. What is your capital-allocation priority order now — internal pipeline, M&A, or buybacks — and what would make you accelerate the buyback beyond $1bn?
10. What is the current best estimate of the Moderna patent-litigation exposure on Comirnaty, and how is liability shared with Pfizer across jurisdictions?
11. Which two or three pipeline readouts in the next 18 months would you tell shareholders are genuinely thesis-defining?
12. How do you intend to build commercial/oncology-launch capability — organically or via partners like BMS — given you've never launched a cancer drug?
13. What inherited liabilities (CureVac EU-Commission APA audit, CureVac obligations) could be financially material?
14. Does the PFIC status and the offshore cash structure constrain how you can return capital to US ADS holders?
15. What is the single assumption in your internal plan that, if wrong, most threatens the oncology pivot?

---